CD19-directed CAR T-cell therapy is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells that express CD19, a protein found on most B-cell lymphomas. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.